Form D · Biotechnology
VANQUA BIO, INC.
Chicago, IL · CIK 0001790072
Offering snapshot reported Jul 5, 2024 · SEC filing
- Reported sold
- $45M Offering amount: $45M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 15, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 5, 2024 | Initial | $44,979,987 | No comparison | 12 | SEC filing |
| Sep 15, 2021 | Initial | $84,999,987 | No comparison | 11 | SEC filing |
| Oct 7, 2019 | Initial | $6,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-517876
Source: Form D, filed Jul 5, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mona Ashiya | Director |
| Uya Chuluunbaatar | Director |
| Bernard Davitian | Director |
| Viola Meehan | Executive |
| Sara Nayeem | Director |
| Jonathan Silverstein | Director |
| Stephen Squinto | Director |
| James Sullivan | Director, Executive |
| Rand Sutherland | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1375 W Fulton Street Ste. 600
Chicago, IL, 60607
Chicago, IL, 60607